Freestone Capital Holdings LLC Acquires 630 Shares of DexCom, Inc. (NASDAQ:DXCM)

Freestone Capital Holdings LLC raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,235 shares of the medical device company’s stock after acquiring an additional 630 shares during the period. Freestone Capital Holdings LLC’s holdings in DexCom were worth $1,974,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Bank of New Hampshire bought a new stake in shares of DexCom during the first quarter worth about $1,508,000. abrdn plc grew its holdings in shares of DexCom by 21.1% during the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock worth $47,221,000 after purchasing an additional 66,348 shares during the last quarter. Cerity Partners LLC grew its holdings in shares of DexCom by 5,791.0% during the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock worth $57,574,000 after purchasing an additional 456,097 shares during the last quarter. Eagle Asset Management Inc. grew its holdings in shares of DexCom by 21.5% during the fourth quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock worth $217,929,000 after purchasing an additional 310,728 shares during the last quarter. Finally, Alberta Investment Management Corp grew its holdings in shares of DexCom by 27.0% during the fourth quarter. Alberta Investment Management Corp now owns 323,335 shares of the medical device company’s stock worth $40,123,000 after purchasing an additional 68,723 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on DXCM shares. Royal Bank of Canada reduced their price target on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a report on Friday. Wells Fargo & Company reduced their price target on DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a report on Friday. Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 target price on shares of DexCom in a report on Tuesday. JPMorgan Chase & Co. cut DexCom from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $145.00 to $75.00 in a report on Friday. Finally, Robert W. Baird cut DexCom from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $161.00 to $80.00 in a report on Friday. Six investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $112.60.

Insider Transactions at DexCom

In other news, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $113.55, for a total transaction of $113,550.00. Following the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Bridgette P. Heller sold 1,000 shares of the stock in a transaction on Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the sale, the director now directly owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Jereme M. Sylvain sold 745 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $85,712.25. Following the completion of the sale, the chief financial officer now directly owns 84,948 shares of the company’s stock, valued at $9,773,267.40. The disclosure for this sale can be found here. Insiders have sold 4,112 shares of company stock valued at $480,861 over the last ninety days. 0.30% of the stock is owned by company insiders.

DexCom Trading Down 41.1 %

DXCM traded down $44.29 during trading on Friday, hitting $63.56. The company’s stock had a trading volume of 40,282,656 shares, compared to its average volume of 3,182,912. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The stock’s fifty day moving average price is $116.63 and its 200-day moving average price is $124.29. The firm has a market capitalization of $25.28 billion, a P/E ratio of 40.41, a PEG ratio of 2.74 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same period in the previous year, the firm earned $0.34 earnings per share. The company’s revenue was up 15.3% compared to the same quarter last year. Analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.